Production (Stage)
Cytosorbents Corporation
CTSO
$0.845
-$0.004-0.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 33.79% | -30.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.79% | -30.53% | |||
| Cost of Revenue | 1,116.38% | -106.03% | |||
| Gross Profit | -8.32% | 28.20% | |||
| SG&A Expenses | -14.25% | 26.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.92% | -20.70% | |||
| Operating Income | 10.82% | -0.61% | |||
| Income Before Tax | 84.56% | -310.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 81.25% | -237.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.25% | -237.77% | |||
| EBIT | 10.82% | -0.61% | |||
| EBITDA | 11.35% | -0.51% | |||
| EPS Basic | 83.14% | -235.90% | |||
| Normalized Basic EPS | 86.55% | -332.95% | |||
| EPS Diluted | 83.14% | -235.90% | |||
| Normalized Diluted EPS | 86.55% | -332.95% | |||
| Average Basic Shares Outstanding | 11.00% | 0.48% | |||
| Average Diluted Shares Outstanding | 11.00% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||